



1Fu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 9517**  
Tsuyoshi SUZUKI et al. : Attorney Docket No. 2004\_1909A  
Serial No. 10/516,360 : Group Art Unit 1625  
Filed March 4, 2005 : Examiner Taofiq A. Solola

PREVENTIVES AND/OR REMEDIES  
FOR SUBJECTS WITH THE EXPRESSION OR  
ACTIVATION OF Her2 AND/OR EGFR : **Mail Stop: AMENDMENT**

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated December 31, 2007, Applicants hereby elect the invention identified as Group II (claims 19-24), drawn to a method; as a representative, N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-methyl-3-(4-methyl-1-piperazinyl)-1-butynyl]-6-quinazolinyl}acrylamide which is the penultimate compound presented in claim 16; and cancer as a specific disease.

Favorable action on the merits is now requested.

Respectfully submitted,  
Tsuyoshi SUZUKI et al.

By: Wacheek

Warren M. Cheek  
Registration No. 33,367  
Attorney for Applicants

WMC/WRS/lq  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
January 31, 2008